Get the Stockscreener App
2.38
4.39%
0.10
After Hours:
2.38
Akebia Therapeutics Inc stock is traded at $2.38, with a volume of 2.25M.
It is up +4.39% in the last 24 hours and up +22.05% over the past month.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
See More
Previous Close:
$2.28
Open:
$2.26
24h Volume:
2.25M
Relative Volume:
0.60
Market Cap:
$540.75M
Revenue:
$194.75M
Net Income/Loss:
$-51.26M
P/E Ratio:
-8.50
EPS:
-0.28
Net Cash Flow:
$-23.38M
1W Performance:
+15.53%
1M Performance:
+22.05%
6M Performance:
+49.69%
1Y Performance:
+78.95%
1-Day Range:
$2.26
$2.40
1-Week Range:
$2.01
$2.40
52-Week Range:
$0.80
$2.89
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Name
Akebia Therapeutics Inc
Sector
Phone
617-871-2098
Address
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
2.38 | 540.75M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
153.47 | 65.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 46.99B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.18 | 45.96B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
14.87 | 17.04B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
291.38 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-01-25 | Initiated | Jefferies | Buy |
| Nov-29-23 | Resumed | BTIG Research | Buy |
| Aug-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-31-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-31-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-22 | Downgrade | Needham | Buy → Hold |
| Mar-31-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-19 | Reiterated | Needham | Buy |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-11-19 | Reiterated | H.C. Wainwright | Buy |
| May-02-19 | Initiated | JP Morgan | Overweight |
| Mar-20-19 | Initiated | Citigroup | Neutral |
| Sep-07-18 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-18 | Reiterated | Needham | Buy |
| Jun-06-18 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-17 | Initiated | Piper Jaffray | Overweight |
| Dec-07-17 | Initiated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-10-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | Needham | Buy |
| Dec-27-16 | Reiterated | H.C. Wainwright | Buy |
| Dec-20-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-15-16 | Initiated | Aegis Capital | Buy |
| Sep-29-16 | Initiated | Brean Capital | Buy |
| Mar-16-16 | Reiterated | Needham | Buy |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
View All
Akebia Therapeutics Inc Stock (AKBA) Latest News
Lobbying Update: $45,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed - Nasdaq
Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock - Barchart.com
US High Growth Tech Stocks to Watch in 2023 - Yahoo Finance
Akebia Therapeutics : Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones - MarketScreener
Akebia Therapeutics gets EU positive recommendation for Xoanacyl - MSN
Akebia Therapeutics Announces Positive Opinion of European - GlobeNewswire
EMA panel endorses Akebia’s kidney disease treatment By Investing.com - Investing.com Australia
EMA panel endorses Akebia’s kidney disease treatment - Investing.com India
Akebia Therapeutics Says EMA Panel Recommends Approval of Xoanacyl for Chronic Kidney Disease Treatment - MarketScreener
Akebia Therapeutics' (AKBA) Xoanacyl Receives EMA Panel Endorsem - GuruFocus
Akebia says kidney drug endorsed in EU (AKBA:NASDAQ) - Seeking Alpha
Akebia Therapeutics EC Will Review CHMP Recommendation, Final Decision Expected In About Two Months - MarketScreener
Major Win for Akebia: EMA Committee Recommends Novel Dual-Action Kidney Disease Treatment - Stock Titan
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
AVEROA Receives Positive Opinion from the European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD) - The Manila Times
AVEROA Receives Positive Opinion from the European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD) - GlobeNewswire Inc.
Akebia Therapeutics Expands Team with Strategic Stock Options for 8 Key Hires - Stock Titan
Jefferies Initiates Coverage of Akebia Therapeutics (AKBA) with Buy Recommendation - Nasdaq
Jefferies sets Akebia Therapeutics stock at Buy, $6 price target By Investing.com - Investing.com Canada
Jefferies Initiates Akebia Therapeutics at Buy With $6 Price Target - MarketScreener
Akebia initiated with a Buy at Jefferies - TipRanks
Analysts Love These 2 Growth Stocks That Have Over 200% Upside Potential - MSN
Piper Sandler maintains Akebia stock with $6 price target By Investing.com - Investing.com Canada
Akebia Therapeutics to Present Research at National Kidney Foundation Spring Clinical Meetings 2025 - Nasdaq
Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025 - GlobeNewswire
Breakthrough Kidney Disease Treatment Data: Akebia's Vadadustat Shows Promising Results - Stock Titan
Akebia Therapeutics’ $50 Million Common Stock Offering - Global Legal Chronicle
Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering - MSN
Akebia Stock Drops 28% On Pricing Of $50M Common Stock Offering - Barchart
Akebia's Valuation Looks Stretched Despite Auryxia’s Loss Of Exclusivity (NASDAQ:AKBA) - Seeking Alpha
Why Akebia Therapeutics Inc. (AKBA) Went Down On Thursday? - MSN
Akebia Therapeutics Announces $50 Mln Public Offering Of Common Stock - Nasdaq
Akebia Therapeutics Announces Public Offering Pricing - TipRanks
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Crude Oil Gains Over 1%; US Weekly Jobless Claims Increase - Benzinga
JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 33% - Simply Wall St
Akebia Therapeutics tumbles on deep-discounted $50 mln stock sale - TradingView
Why Five Below Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Akebia Therapeutics Prices $50 Million Public Offering -March 20, 2025 at 04:19 am EDT - Marketscreener.com
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewswire
Akebia Therapeutics Announces Pricing Of Public Offering Of Common Stock -March 19, 2025 at 10:18 pm EDT - Marketscreener.com
Akebia Therapeutics Raises $50M: Major Stock Offering Priced at $2.00 Per Share - StockTitan
‘Buckle Up for Another Surge,’ Says Cowen About Nvidia Stock - The Globe and Mail
Akebia Therapeutics launches public stock offering By Investing.com - Investing.com South Africa
2 No-Brainer Biotech Stocks to Buy Right Now - The Globe and Mail
Akebia Therapeutics Inc Stock (AKBA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Akebia Therapeutics Inc Stock (AKBA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Burke Steven Keith | SVP, Chief Medical Officer |
Mar 03 '25 |
Sale |
1.83 |
7,144 |
13,074 |
809,090 |
0.00%
1.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):